ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting
November 04 2021 - 9:00AM
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a
clinical-stage immuno-oncology company developing therapies to
block the CD47 checkpoint pathway, today announced the Company will
be presenting early clinical data from ASPEN-02, its ongoing Phase
1/2 study evaluating evorpacept in combination with azacitidine for
the treatment of myelodysplastic syndromes (“MDS”) in a poster
presentation at the 63rd American Society of Hematology (“ASH”)
Annual Meeting held December 11-14, 2021 in Atlanta, Georgia.
Key Abstract Data
As of July 15, 2021, 13 subjects with newly
diagnosed (“ND”) higher risk or relapsed/refractory (“R/R”) MDS
were enrolled into phase 1 cohorts receiving escalating doses of
evorpacept (20 mg/kg Q2W, 30 mg/kg Q2W, and 60 mg/kg Q4W) combined
with standard doses of azacitidine. Of the 7 ND subjects, 4 had
therapy-related MDS, and 5 had TP53 mutation with complex
cytogenetics. Of the 6 R/R subjects, all had received at least one
hypomethylating agent-based regimen.
Among the 5 ND subjects evaluable for response
(all with TP53 mutation), there were 2 subjects with cytogenetic
response who met criteria for complete response (“CR”) subsequent
to the date of this abstract, 1 subject with a best response of
marrow complete response (“mCR”) with hematologic improvement
(“HI”), and 1 subject each with stable disease (“SD”) and
progressive disease (“PD”). Of the 4 ND subjects who were
transfusion dependent at baseline, 2 achieved transfusion
independence. Among the 5 R/R subjects evaluable for response,
there were 2 subjects with a best response of mCR, 2 with SD, and 1
with PD. No dose-limiting toxicities were observed in any cohort
and no maximum tolerated dose was reached. Additional results will
be presented at the conference.
Poster Presentation Details
Title: Evorpacept
(ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in
Combination with Azacitidine: A Phase 1/2 Study in Patients with
Myelodysplastic Syndrome (ASPEN-02)
Session Name: 637.
Myelodysplastic Syndromes – Clinical and Epidemiological: Poster
II
Presentation Date and Location:
December 12, 2021, 6:00pm – 8:00pm ET, Georgia World Congress
Center, Hall B5
Publication Number: 2601
About ALX Oncology
ALX Oncology is a publicly traded,
clinical-stage immuno-oncology company focused on helping patients
fight cancer by developing therapies that block the CD47 checkpoint
pathway and bridge the innate and adaptive immune system. ALX
Oncology’s lead product candidate, evorpacept, is a next generation
CD47 blocking therapeutic that combines a high-affinity CD47
binding domain with an inactivated, proprietary Fc domain.
Evorpacept has demonstrated promising clinical responses across a
range of hematologic and solid malignancies in combination with a
number of leading anti-cancer agents. ALX Oncology intends to
continue clinical development of evorpacept for the treatment of
multiple solid tumor indications and hematologic malignancies,
including acute myeloid leukemia and myelodysplastic syndromes.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains forward-looking
statements that involve substantial risks and uncertainties.
Forward-looking statements include statements regarding future
results of operations and financial position, business strategy,
product candidates, planned preclinical studies and clinical
trials, results of clinical trials, research and development costs,
regulatory approvals, timing and likelihood of success, plans and
objects of management for future operations, as well as statements
regarding industry trends. Such forward-looking statements are
based on ALX Oncology’s beliefs and assumptions and on information
currently available to it on the date of this press release.
Forward-looking statements may involve known and unknown risks,
uncertainties and other factors that may cause ALX Oncology’s
actual results, performance or achievements to be materially
different from those expressed or implied by the forward-looking
statements. These and other risks are described more fully in ALX
Oncology’s filings with the Securities and Exchange Commission
(“SEC”), including ALX Oncology’s Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q and other documents ALX Oncology
files with the SEC from time to time. Except to the extent required
by law, ALX Oncology undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Investor Contact:
Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Argot Partners
(212)-600-1902
alxoncology@argotpartners.com
Media Contact:
Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From Mar 2024 to Apr 2024
ALX Oncology (NASDAQ:ALXO)
Historical Stock Chart
From Apr 2023 to Apr 2024